TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37858103

Group type: EXPERIMENTAL
Intervention: New birthing room design
Number of subjects: 21
Study: 37858132

Group type: EXPERIMENTAL
Intervention: Standard treatment for OMD
Number of subjects: 32
Study: 37858161

Group type: EXPERIMENTAL
Intervention: Remotely supervised home-based exercise program (12 weeks, 2 sessions/week for first 6 weeks, 3 sessions/week for remaining 6 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommendations for physical activity based on the Physical Activity Guide for the Brazilian Population
Number of subjects: 0
Study: 37858184

Group type: EXPERIMENTAL
Intervention: GT90001 plus nivolumab
Number of subjects: 20
Study: 37858195

Group type: EXPERIMENTAL
Intervention: cfDNA from ascites
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCNA analysis on ascitic cfDNA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCNA profiles on ascites and tumor
Number of subjects: 20
Study: 37858212

Group type: EXPERIMENTAL
Intervention: RPP group (low-dose and low-concentration iodine contrast medium)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: RPP group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 52
Study: 37858247

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) supplementation, 4 IU/day subcutaneous from the beginning of ovarian stimulation (OS) to the trigger day.
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) supplementation
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control group (no GH supplementation)
Number of subjects: 412
Study: 37858249

Group type: EXPERIMENTAL
Intervention: Online, group-based Unified Protocol (UP) intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 180
Study: 37858262

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) components
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: CPT components
Number of subjects: 270
Study: 37858328

Group type: EXPERIMENTAL
Intervention: Emicizumab (6 and 3 mg/kg on days 1 and 2, 1·5 mg/kg weekly until week 12)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 47
Study: 37858585

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV followed by MVA-BN-Filo (Ebola vaccine group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Meningococcal quadrivalent conjugate vaccine (control group)
Number of subjects: 108
Study: 37858599

Group type: EXPERIMENTAL
Intervention: Increased or decreased upper airway volume (UAV) measured in 3-dimensional computed tomography.
Number of subjects: 54
Study: 37858617

Group type: EXPERIMENTAL
Intervention: Lavender essential oil aromatherapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (jojoba oil)
Number of subjects: 112
Study: 37858720

Group type: EXPERIMENTAL
Intervention: LVIS/LVIS Jr devices
Number of subjects: 130
Study: 37858724

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B12 status at gestational weeks 18 and 36
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Infant vitamin B12 status at 3 and 6 months
Number of subjects: 136

Group type: COMPARATOR
Intervention: Breastfeeding status
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Maternal supplement use during pregnancy
Number of subjects: 136
Study: 37858758

Group type: EXPERIMENTAL
Intervention: Hybrid resection (HR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional resection (CR)
Number of subjects: 20
Study: 37858867

Group type: EXPERIMENTAL
Intervention: Oral therapy after 3-5 days of IV therapy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Oral therapy
Number of subjects: 165
Study: 37859587

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 102
Study: 37859647

Group type: EXPERIMENTAL
Intervention: Narrow band green light (NbGL) treatment during migraine attacks
Number of subjects: 698
Study: 37859672

Group type: EXPERIMENTAL
Intervention: dupilumab 200/300 mg
Number of subjects: 0
Study: 37859748

Group type: EXPERIMENTAL
Intervention: Medium-dose ahaMSCs-Exos (intranasally administered two times per week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37859768

Group type: EXPERIMENTAL
Intervention: tDCS plus cognitive intervention
Number of subjects: 70
Study: 37860154

Group type: EXPERIMENTAL
Intervention: Combined training programme in individual practice at home (n=53)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combined training programme in group practice in a gymnasium (n=53)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combined training programme in group practice in an enriched environment (n=53)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Combined training programme (all groups)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 159
Study: 37860278

Group type: EXPERIMENTAL
Intervention: BNT141 mRNA-LNP
Number of subjects: 0

Group type: COMPARATOR
Intervention: IMAB362/Zolbetuximab
Number of subjects: 0
Study: 37860578

Group type: EXPERIMENTAL
Intervention: Menstrual Cups (MC)
Number of subjects: 4137

Group type: EXPERIMENTAL
Intervention: Cash Transfers (CCT)
Number of subjects: 4137

Group type: EXPERIMENTAL
Intervention: Combined MC and CCT
Number of subjects: 4137

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4137
Study: 37860863

Group type: EXPERIMENTAL
Intervention: Evinacumab 15 mg/kg every 4 weeks
Number of subjects: 14
Study: 37861217

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328

Group type: COMPARATOR
Intervention: Teplizumab and Placebo
Number of subjects: 328
Study: 37861218

Group type: EXPERIMENTAL
Intervention: Tarlatamab 10 mg every 2 weeks
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Tarlatamab 100 mg every 2 weeks
Number of subjects: 220
Study: 37861407

Group type: EXPERIMENTAL
Intervention: AGS15E at 1.00 mg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AGS15E in total population
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AGS15E in CPI-exposed subgroup
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AGS15E at doses of ≥0.75 mg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AGS15E at doses of 0.50 to 1.25 mg/kg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: AGS15E
Number of subjects: 93
Study: 37861675

Group type: EXPERIMENTAL
Intervention: Infant nevirapine
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HBeAg positivity
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HBV active drugs (HBV-ARV)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: HBV-ARV
Number of subjects: 2016
Study: 37861683

Group type: EXPERIMENTAL
Intervention: Dynamic choice HIV prevention (DCP) intervention
Number of subjects: 403

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 403
Study: 37861929

Group type: EXPERIMENTAL
Intervention: Q.Clear algorithm with β-factors ranging from 100 to 3500
Number of subjects: 0
Study: 37861988

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Cognitive Behavioral Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Community Care
Number of subjects: 0
Study: 37861993

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab, Paclitaxel, and Carboplatin (ABCP)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Pemetrexed plus Carboplatin or Cisplatin (PC)
Number of subjects: 228
Study: 37862013

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and Velpatasvir 100 mg for 12 weeks (2-week starter pack provided at diagnosis)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir treatment
Number of subjects: 492
Study: 37862075

Group type: EXPERIMENTAL
Intervention: Wisepill adherence monitor for 3 months with options for SMS reminders, social supporter, or alarm reminder.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Wisepill adherence monitor for 3 months.
Number of subjects: 15
Study: 37862083

Group type: EXPERIMENTAL
Intervention: Primary allied health care (dietitians, exercise therapists, occupational therapists, physical therapists, speech and language therapists)
Number of subjects: 1451

Group type: EXPERIMENTAL
Intervention: Primary allied health care
Number of subjects: 1451
Study: 37862103

Group type: EXPERIMENTAL
Intervention: Healium
Number of subjects: 327

Group type: COMPARATOR
Intervention: Healing Choices
Number of subjects: 327
Study: 37862324

Group type: EXPERIMENTAL
Intervention: Skills to Enhance Positivity (STEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 0
Study: 37862463

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 2335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2335

Group type: EXPERIMENTAL
Intervention: None (pretrial population)
Number of subjects: 2335
Study: 37862670

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) app
Number of subjects: 449

Group type: COMPARATOR
Intervention: Health education sham app
Number of subjects: 449
Study: 37862791

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 317
Study: 37862823

Group type: EXPERIMENTAL
Intervention: Oral omega-3 fatty acids capsules (1 g daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Matching placebo (control group)
Number of subjects: 70
Study: 37862832

Group type: EXPERIMENTAL
Intervention: CANKADO-active arm (supported by CANKADO PRO-React)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CANKADO-inform arm (drug intake documentation only)
Number of subjects: 0
Study: 37863080

Group type: EXPERIMENTAL
Intervention: Rusfertide (10 mg once weekly for 24 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rusfertide
Number of subjects: 16
Study: 37863084

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous insulin icodec
Number of subjects: 582

Group type: COMPARATOR
Intervention: Once-daily insulin degludec
Number of subjects: 582
Study: 37863088

Group type: EXPERIMENTAL
Intervention: CD19-directed CAR T cells
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CD22-directed CAR T cells
Number of subjects: 81
Study: 37863158

Group type: COMPARATOR
Intervention: Standard opioid prescription protocol (3-10 tablets of 5 mg oxycodone upon discharge)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Restrictive opioid prescription protocol (no opioid prescription unless requested)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard opioid prescription protocol
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Restrictive opioid prescription protocol
Number of subjects: 133
Study: 37863161

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37863160

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 241
Study: 37863195

Group type: EXPERIMENTAL
Intervention: 50 mcg intrathecal morphine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 150 mcg intrathecal morphine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 250 mcg intrathecal morphine
Number of subjects: 72
Study: 37863268

Group type: EXPERIMENTAL
Intervention: Household-level income-generating agricultural intervention
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 62
Study: 37863398

Group type: EXPERIMENTAL
Intervention: Adaptations to naloxone provision during the COVID-19 pandemic
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Adaptations to OTC syringe sales during the COVID-19 pandemic
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Overall adaptations perceived by pharmacy staff
Number of subjects: 134
Study: 37863418

Group type: EXPERIMENTAL
Intervention: Oxygen reserve index-guided oxygen titration
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard oxygen titration based on pulse oximetry
Number of subjects: 92
Study: 37863590

Group type: COMPARATOR
Intervention: Intracranial pressure monitoring only
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Both intracranial pressure and brain tissue oxygen pressure monitoring
Number of subjects: 318
Study: 37863608

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 101
Study: 37863785

Group type: EXPERIMENTAL
Intervention: Dry heat application
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dry cold application
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 37863878

Group type: EXPERIMENTAL
Intervention: Laparoscopic TME with Denonvilliers' fascia preservation (L-DVF-P)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Laparoscopic TME with Denonvilliers' fascia resection (L-DVF-R)
Number of subjects: 262
Study: 37863916

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg on day 1) plus nab-paclitaxel (125 mg/m2) and epirubicin (dosage not specified)
Number of subjects: 0
Study: 37864049

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus concurrent chemo-radiotherapy (CCRT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo plus concurrent chemo-radiotherapy (CCRT)
Number of subjects: 201
Study: 37864139

Group type: EXPERIMENTAL
Intervention: At-home computerized executive function training for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 37864152

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiation therapy (SABR) in addition to standard of care (Arm 2)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard of care therapy (Arm 1)
Number of subjects: 270
Study: 37864156

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin
Number of subjects: 32
Study: 37864195

Group type: EXPERIMENTAL
Intervention: Tranexamic acid-soaked gelatin sponge
Number of subjects: 63
Study: 37864209

Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 50
Study: 37864252

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) therapy through an immersive VR garden intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (traditional post-stroke rehabilitation program without VR therapy)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Gender comparison in the experimental group (women)
Number of subjects: 83
Study: 37864258

Group type: EXPERIMENTAL
Intervention: CommunityRx intervention for caregivers of hospitalized children (CommunityRx-Hunger)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: CommunityRx intervention for caregivers of community-residing people with dementia (CommunityRx-Dementia)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: CommunityRx intervention for both trials
Number of subjects: 639
Study: 37864269

Group type: EXPERIMENTAL
Intervention: FIRST (transdiagnostic intervention built on five empirically supported principles of change)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study: 37864281

Group type: EXPERIMENTAL
Intervention: Lisinopril (0.05 to 0.2 mg/kg, oral, once daily in the morning)
Number of subjects: 13
Study: 37864313

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Number of subjects: 429
Study: 37864337

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel plus durvalumab followed by maintenance durvalumab plus olaparib
Number of subjects: 718

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel plus durvalumab placebo followed by placebo maintenance
Number of subjects: 718
Study: 37864379

Group type: EXPERIMENTAL
Intervention: beinaglutide alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: insulin glargine (IGlar)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: beinaglutide combined with insulin glargine (IGlar)
Number of subjects: 68
Study: 37864583

Group type: EXPERIMENTAL
Intervention: Nutritional stabilization and medical treatment during hospitalization (mean hospitalization: 6 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Discharge assessments after nutritional stabilization
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Follow-up assessments up to 6 months after discharge
Number of subjects: 33
Study: 37864592

Group type: EXPERIMENTAL
Intervention: 1.11 GBq/cycle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1.85 GBq/cycle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2.59 GBq/cycle
Number of subjects: 13
Study: 37864596

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lifestyle therapy (Control)
Number of subjects: 58
Study: 37864646

Group type: EXPERIMENTAL
Intervention: PT2385 (800 mg b.i.d.)
Number of subjects: 24
Study: 37864735

Group type: EXPERIMENTAL
Intervention: Single Anastomosis Duodenal Switch (SADI-S)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Classic Duodenal Switch (DS)
Number of subjects: 62
Study: 37864852

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 128
Study: 37864885

Group type: EXPERIMENTAL
Intervention: 4-(3-1H-indazolyl)amino quinazoline derivatives (compounds 27e, 27g, 27i, and 27j)
Number of subjects: 0
Study: 37865043

Group type: EXPERIMENTAL
Intervention: 5 μg vaccine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 15 μg vaccine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 45 μg vaccine
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: One 45 μg dose of vaccine followed by placebo (Part 1 only)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 37865048

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (NTZ) combined with concurrent chemoradiotherapy (CCRT)
Number of subjects: 56
Study: 37865138

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) 380 mg/month
Number of subjects: 143

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX) 8-24/2-6 mg daily
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 143
Study: 37865216

Group type: EXPERIMENTAL
Intervention: Severe postpartum pain (VNS ≥ 8)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EPDS > 10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rooming in with the baby
Number of subjects: 0
Study: 37865291

Group type: EXPERIMENTAL
Intervention: miR-122 and miR-21
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-144
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-mer model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7-mer model (adenocarcinoma only)
Number of subjects: 0
Study: 37865397

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg) and tremelimumab (75 mg) with neoadjuvant chemotherapy (NAC) for three cycles, followed by interval debulking surgery (IDS), then durvalumab (1120 mg) and adjuvant chemotherapy for three cycles, followed by durvalumab maintenance (1120 mg for total 12 cycles).
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) combined with durvalumab and tremelimumab.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAEs) from durvalumab and tremelimumab.
Number of subjects: 23
Study: 37865411

Group type: EXPERIMENTAL
Intervention: Managed problem-solving plus (MAPS+) delivered by community health workers (CHWs)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Menu of implementation strategies
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Implementation strategies for MAPS+
Number of subjects: 390
Study: 37865101

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 28 days
Number of subjects: 4271

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 4271

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 4271
Study: 37865418

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2% mepivacaine
Number of subjects: 200
Study: 37865470

Group type: EXPERIMENTAL
Intervention: Intravitreal 15 mg per 0.1 mL pegcetacoplan (monthly)
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Intravitreal 15 mg per 0.1 mL pegcetacoplan (every other month)
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1258
Study: 37865685

Group type: EXPERIMENTAL
Intervention: RAND-36 questionnaire measuring HRQoL 3-9 months after ICU discharge
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Pulmonary illness
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Psychiatric diagnosis
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Patients treated in ICU for COVID-19
Number of subjects: 252
Study: 37865736

Group type: EXPERIMENTAL
Intervention: Surf tablet usage
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Surf tablet usage among satisfied parents
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: eHealth literacy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Healthcare satisfaction
Number of subjects: 32
Study: 37865752

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol (TC) levels in men aged 45 years or older
Number of subjects: 20544

Group type: COMPARATOR
Intervention: Serum total cholesterol (TC) levels in women of different ages
Number of subjects: 20544